Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07523282) titled 'Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases' on April 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd
Condition:
Autoimmune Disease
Intervention:
Drug: HN2302 Injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: April 28, 2026
Target Sample Size: 12
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07523282
Published by HT Dig...